Recent Updates
Recently added Catalysts

oxytocin

Phase 1

Postpartum Hemorrhage | Small molecule | Other |GSK plc|Last Updated: Oct 19, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment16
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02542813Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female VolunteersPHASE1 COMPLETED 16Sep 14, 2015Dec 16, 2015Oct 19, 20171 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of subjects with adverse events (AEs)
Up to 16 weeks

An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Absolute values and changes over time of haematology from pre-dose values as a measure of safety and tolerability
Up to 20 weeks

Hematology assessments will be performed for the following parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, white blood cells (WBC) (absolute), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), neutrophils, lymphocytes, monocytes, eosinophils, and basophils.

Absolute values and changes over time of clinical chemistry from pre-dose values as a measure of safety and tolerability
Up to 20 weeks

Clinical chemistry assessments will be performed for the following parameters: blood urea nitrogen (BUN), creatinine, glucose, potassium, sodium, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total and direct bilirubin, total protein, and albumin.

Absolute values and changes over time of urinalysis from pre-dose values as a measure of safety and tolerability
Up to 20 weeks

Dipstick method will be used to measure pH, glucose, protein, blood and ketones.

Absolute values and changes over time of blood pressure from pre-dose values as a measure of safety and tolerability
Up to 20 weeks

Three readings of blood pressure will be taken at screening (single readings at all other time-points).

Absolute values and changes over time of pulse rate from pre-dose values as a measure of safety and tolerability
Up to 20 weeks

Three readings of pulse rate will be taken at screening (single readings at all other time-points).

Absolute values and changes over time of heart rate from pre-dose values as a measure of safety and tolerability
Up to 20 weeks

Absolute values and changes over time of heart rate from pre-dose values as a measure of safety and tolerability.

Absolute values and changes over time of 12-lead electrocardiogram (ECG) parameters (PR, QRS, QT, corrected QT [QTc] intervals) from pre-dose values as a measure of safety and tolerability
Up to 20 weeks

Triplicate 12-lead ECGs will be obtained screening and predose (predose IM oxytocin), and single 12-lead ECGs at all other time-points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.

Number of subjects with adverse respiratory events as monitored by spirometry including forced expiratory volume in 1 second (FEV1.0) and pulse oximetry as a measure of specific respiratory safety
Up to 16 weeks

FEV1 is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. Pulse oximetry is a procedure used to measure the oxygen level (or oxygen saturation) in the blood.

Plasma concentration profile for IH oxytocin
Day 1, 2, and 3 of dosing session 1, and Day 1 of dosing session 2, 3, and 4

Blood samples will be withdrawn from subjects at pre dose, 3 minutes (mins), 5 mins, 10 mins, 20 mins, 0.5h, 0.75h, 1 hour (h), 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 8 h, and 24 h (24 h post dose assessments only applicable to Dosing Session 1, Group 1 and the first 3 subjects at each new dose level \[Dosing Sessions 2 -4\]).

Plasma concentration profile for 10 IU IM oxytocin
Day 1, 2, and 3 of dosing session 1, and Day 1 of dosing session 2, 3, and 4

Blood samples will be withdrawn from subjects at pre dose, 3 mins, 5 mins, 10 mins, 20 mins, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, and 8 h.

Composite PK parameters for IH oxytocin: maximum plasma concentration (Cmax), last quantifiable concentration (Clast), time to Cmax (tmax), area under the plasma concentration-time curve (AUC) and terminal phase half-life (t1/2)
Day 1, 2, and 3 of dosing session 1, and Day 1 of dosing session 2, 3, and 4

Blood samples will be withdrawn from subjects at pre dose, 3 mins, 5 mins, 10 mins, 20 mins, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 8 h, and 24 h (24 h post dose assessments only applicable to Dosing Session 1, Group 1 and the first 3 subjects at each new dose level \[Dosing Sessions 2 -4\]).

Composite PK parameters for 10 IU IM oxytocin: Cmax, Clast, tmax, AUC and t1/2
Day 1, 2, and 3 of dosing session 1, and Day 1 of dosing session 2, 3, and 4

Blood samples will be withdrawn from subjects at pre dose, 3 mins, 5 mins, 10 mins, 20 mins, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, and 8 h.

Secondary Endpoints
Composite of PK parameters: Cmax and AUC will be compared as data permit
Day 1, 2, and 3 of dosing session 1, and Day 1 of dosing session 2, 3, and 4
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelFACTORIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)EXPERIMENTALSubjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
IM oxytocin - IH placebo/IH oxytocin (50)EXPERIMENTALSubjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
Interventions
NameTypeDescription
IM oxytocin 10 IUDRUGIM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
IH oxytocin 50 mcgDRUGIH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
IH oxytocin 200 mcgDRUGIH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
IH oxytocin 400 mcgDRUGIH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
IH oxytocin 600 mcgDRUGIH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
PlaceboDRUGPlacebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Between 18 and 45 years of age inclusive, at the time of signing the informed consent. * Premenopausal women on an oestrogen-containing oral contraceptive pill (OCP) for a 12 month minimum period and to continue their current OCP schedule for the duration of the clinical study...

Countries:United Kingdom
Unlock Eligibility Criteria